Previous 10 | Next 10 |
Source: ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
Allergan (NYSE: AGN ) is scheduled to announce Q3 earnings results on Tuesday, November 5th, before market open. The consensus EPS Estimate is $4.20 (-1.2% Y/Y) and the consensus Revenue Estimate is $3.88B (-0.8% Y/Y). Over the last 2 years, agn has beaten EPS estimates 100% of the t...
The Institute for Clinical and Economic Review (ICER), a Boston-based nonpartisan nonprofit with no policy-making role, has emerged as a major influencer on pricing by drugmakers. More news on: Sanofi, Regeneron Pharmaceuticals, Inc., Amgen Inc., Healthcare stocks news, News on ETFs, ...
AbbVie ( ABBV ) Q3 results : Revenues: $8,479M (+3.0%); Immunology: $5,041M (-1.6%); Hematologic Oncology: $1,478M (+38.3%); HCV: $698M (-19%). More news on: AbbVie Inc., Allergan plc, Healthcare stocks news, Earnings news and commentary, Top Breaking stock news, Read more ...
$750 million charge in Allergan’s 3Q 2019 earnings Allergan plc’s ( AGN ) 3Q-2019 earnings will have a $750 million pre-tax GAAP charge. According to the company’s announcement on 10/28/2019, its subsidiaries, Forest Laboratories, LLC, Forest Laboratories, Inc. and F...
Insurance company versus big pharma - whose money is it anyway? Humana Inc. (HUM), a $39 billion health insurance company, accuses Teva Pharmaceutical Industries (TEVA), an $8 billion company, and a few other generic drug makers, of playing ugly in the generic drugs market. In a 610-page c...
SAN FRANCISCO and DUBLIN , Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced that the U.S. Food and Drug Administratio...
NORTH CHICAGO, Ill. , Oct. 25, 2019 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the commencement, in connection with its previously announced acquisition of Allergan plc (NYSE:AGN), of offers to exchange any and all outstanding notes of certain series issued by...
DUBLIN , Oct. 25, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the fourth quarter of 2019. The dividend will be paid on December 13, 2019 to shareholders of record at the ...
DUBLIN , Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX ® for the treatment of pediatric patients (2 to 17 years of age) w...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...
2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...
2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...